Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

AZD6234

Phase 3Small molecule

AZD6234 is one of 64 small molecule programs targeting Overweight. It is currently in Phase 3.

3

Indications

13

Total Trials

8

Active Trials

63

Competitors

Pipeline

Status by Indication[3][1]

Indication

OverweightCompleted

Weight LossActive, not recruiting

Obesity or OverweightRecruiting

OverweightPhase 1

Completed

Weight LossPhase 2

Active, not recruiting

Obesity or OverweightPhase 3

Recruiting

Competition

Competitive Landscape

46 competitors in Overweight

#DrugCompanyPhaseTrials

Ozempic

Mounjaro

Glucophage

Taltz

GZR18

GGan & Lee Pharmaceuticals.

IBI362

Innovent Biologics (Suzhou) Co. Ltd.

Retatrutide

HDM1002

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

RAY1225

GGuangdong Raynovent Biotech Co., Ltd

AZD6234

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Hepatic Impairment

NCT07546760

Q3 2027

Phase 1Active, not recruiting

Study completion

NCT07013643

Q3 2028

Phase 3Recruiting

Obesity or Overweight

NCT07784270

Phase 3Recruiting

Obesity or Overweight

NCT07776509

Q2 2029

Phase 3Recruiting

Obesity or Overweight

NCT07784725

Clinical

Trials by Indication[1]

Obesity or Overweight4 trials

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07784725·2,500 enrolled

A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07784270·1,500 enrolled

A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Obesity or Overweight With Comorbidity

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT06595238·262 enrolled

Show 1 more trial

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 as an Adjunct to Incretin-based Therapies in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus (SELENE 3)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07776509·500 enrolled

Overweight2 trials

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT06132841·104 enrolled

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05511025·54 enrolled

Renal Impairment1 trial

Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06845813·24 enrolled

Weight loss1 trial

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06862791·377 enrolled

Hepatic Impairment1 trial

A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD9550 and AZD6234

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07546760·28 enrolled

3 more indications

Obesity & Overweight1 trial

A Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD6234, AZD9550, and AZD6234 in Combination With AZD9550 in Chinese Participants Living With Obesity/Overweight

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07017179·16 enrolled

Endocrinology1 trial

A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT06851858·69 enrolled

Unspecified2 trials

A Phase I, Single-Dose, Open-Label, Sequential, Randomised, Crossover Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD6234 in Participants Living With Overweight or Obesity

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT07220954·19 enrolled

An Open-label, Single-sequence Multiple Cohort Study to Assess the Effect of Multiple Doses of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on the Pharmacokinetics of Single Doses of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07013643·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for AZD6234. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD6234 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD6234. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Related News